J Rheum Dis.  2021 Jul;28(3):113-118. 10.4078/jrd.2021.28.3.113.

Mortality in Korean Patients With Rheumatoid Arthritis

• Lee YK
• Bae SC

• KMID: 2516946
• DOI: http://doi.org/10.4078/jrd.2021.28.3.113

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease in which the abnormal immune system causes arthritis. We reviewed previous studies about the mortality and causes of death in Korean patients with RA. Also, we discussed the association between comorbidities and mortality in Korean patients with RA. In Korea, a few epidemiologic studies reporting mortality rates in patients with RA have been conducted using large databases. According to these data sources, the estimated mortality rate of Korean patients with RA from 1.29% to 1.65%. Despite substantial improvements in RA management, the mortality rate of patients with RA remains higher than that of the general population. Also, the most common cause of death was malignancy, and respiratory disease and cardiovascular disease followed. The malignancy-specific mortality rate of patient with RA was not higher than that of the general population; however, several causes of death, such as respiratory disease and infections, were associated with a higher mortality rate among patients with RA than among the general population. Therefore, to increase the survival rate of patients with RA, attention should be paid to the management of comorbidities as well as to the RA itself.

Keyword

Rheumatoid arthritis; Mortality; Republic of Korea

Reference

1. Björnådal L, Baecklund E, Yin L, Granath F, Klareskog L, Ekbom A. 2002; Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol. 29:906–12. PMID: 12022348.

2. Sokka T, Abelson B, Pincus T. 2008; Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 26(5 Suppl 51):S35–61. PMID: 19026144.

3. Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. 2010; Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 39:360–7. DOI: 10.3109/03009741003604542. PMID: 20476859.

4. Widdifield J, Bernatsky S, Paterson JM, Tomlinson G, Tu K, Kuriya B, et al. 2015; Trends in excess mortality among patients with rheumatoid arthritis in Ontario, Canada. Arthritis Care Res (Hoboken). 67:1047–53. DOI: 10.1002/acr.22553. PMID: 25623141.

5. van den Hoek J, Boshuizen HC, Roorda LD, Tijhuis GJ, Nurmohamed MT, van den Bos GA, et al. 2017; Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 37:487–93. DOI: 10.1007/s00296-016-3638-5. PMID: 28032180. PMCID: PMC5357293.

6. An Y, Liu T, He D, Wu L, Li J, Liu Y, et al. 2017; The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study. Clin Rheumatol. 36:35–43. DOI: 10.1007/s10067-016-3424-5. PMID: 27709444. PMCID: PMC5216094.

7. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al. 2007; Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 66:670–5. DOI: 10.1136/ard.2006.062497. PMID: 17158824. PMCID: PMC1954627.

8. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. 2014; Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 370:2377–86. DOI: 10.1056/NEJMoa1310476. PMID: 24941177.

9. Kim YJ, Shim JS, Choi CB, Bae SC. 2012; Mortality and incidence of malignancy in Korean patients with rheumatoid arthritis. J Rheumatol. 39:226–32. DOI: 10.3899/jrheum.110704. PMID: 22174211.

10. Choi IA, Lee JS, Song YW, Lee EY. 2019; Mortality, disability, and healthcare expenditure of patients with seropositive rheumatoid arthritis in Korea: a nationwide population-based study. PLoS One. 14:e0210471. DOI: 10.1371/journal.pone.0210471. PMID: 30620765. PMCID: PMC6324802.

11. Lee YK, Ahn GY, Lee J, Shin JM, Lee TH, Park DJ, et al. 2021; Excess mortality persists in patients with rheumatoid arthritis. Int J Rheum Dis. 24:364–72. DOI: 10.1111/1756-185X.14058. PMID: 33463890.

12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. 1988; The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315–24. DOI: 10.1002/art.1780310302. PMID: 3358796.

13. Pinheiro FA, Souza DC, Sato EI. 2015; A study of multiple causes of death in rheumatoid arthritis. J Rheumatol. 42:2221–8. DOI: 10.3899/jrheum.150166. PMID: 26472415.

14. Widdifield J, Paterson JM, Huang A, Bernatsky S. 2018; Causes of death in rheumatoid arthritis: how do they compare to the general population? Arthritis Care Res (Hoboken). 70:1748–55. DOI: 10.1002/acr.23548. PMID: 29512334.

15. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. 2014; Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 1:ofu024. DOI: 10.1093/ofid/ofu024. PMID: 25734097. PMCID: PMC4324183.

16. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2016; 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 68:1–25. DOI: 10.1002/acr.22783. PMID: 26545825.

17. Jeong H, Baek SY, Kim SW, Eun YH, Kim IY, Kim H, et al. 2017; Comorbidities of rheumatoid arthritis: results from the Korean National Health and Nutrition Examination Survey. PLoS One. 12:e0176260. DOI: 10.1371/journal.pone.0176260. PMID: 28423031. PMCID: PMC5397042.

18. Kim D, Cho SK, Choi CB, Choe JY, Chung WT, Hong SJ, et al. 2017; Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis. Rheumatol Int. 37:1735–45. DOI: 10.1007/s00296-017-3781-7. PMID: 28748423.

19. Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. 2017; Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 56:344–50. DOI: 10.1093/rheumatology/kex299. PMID: 28957566.

20. Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B. 2015; Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med. 30:104–9. DOI: 10.3904/kjim.2015.30.1.104. PMID: 25589842. PMCID: PMC4293548.

21. Wilson JC, Sarsour K, Gale S, Pethö-Schramm A, Jick SS, Meier CR. 2019; Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 71:498–511. DOI: 10.1002/acr.23611. PMID: 29856128.

22. Krause D, Schleusser B, Herborn G, Rau R. 2000; Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 43:14–21. DOI: 10.1002/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7. PMID: 10643695.

23. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. 2002; Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 359:1173–7. DOI: 10.1016/S0140-6736(02)08213-2. PMID: 11955534.

24. Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, et al. 2007; All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis. 66:880–5. DOI: 10.1136/ard.2006.067660. PMID: 17324968. PMCID: PMC1955107.

25. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. 2015; Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 386:258–65. DOI: 10.1016/S0140-6736(14)61704-9. PMID: 25975452. PMCID: PMC4580232.